Insuman Basal

Insulin human (rDNA), the active ingredient in Insuman Basal, is an insulin presented as a sterile solution for subcutaneous use. It mimics natural human insulin, providing basal glucose control for individuals with type 1 and type 2 diabetes mellitus, and is administered by injection according to a prescriber‑determined regimen.

GNH USA supplies Insuman Basal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, offering reliable sourcing from the European market with adherence to quality standards.

Insuman Basal is a basal insulin that acts on the endocrine system to regulate blood glucose levels in diabetes.

Type 1 diabetes mellitus: provides long‑acting insulin to maintain fasting glucose control. Type 2 diabetes mellitus: added when basal insulin is required to achieve glycaemic targets. Insulin deficiency states: supplements endogenous insulin in patients with inadequate pancreatic secretion.

Insuman Basal may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood sugar episodes, especially if dose is excessive. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase associated with improved glucose utilization. - Lipodystrophy: localized fat accumulation or loss with repeated injections. - Edema: mild fluid retention, particularly in the lower extremities. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe hypoglycaemia: profound low glucose requiring assistance. - Anaphylactic reaction: rare but potentially life‑threatening allergy. - Allergic dermatitis: widespread skin rash or hives. - Insulin‑induced hypokalemia: low potassium levels in severe cases. - Acute insulin edema leading to cardiac decompensation. - Necrotising fasciitis at injection site (extremely rare).

When using Insuman Basal, consider the following precautions.

Dose adjustment: tailor the dose based on regular glucose monitoring and clinical response. Hypoglycaemia risk: educate patients on recognising and treating low blood sugar. Renal impairment: monitor kidney function and adjust dose if necessary. Pregnancy and lactation: use only if benefits outweigh potential risks and under medical supervision. Concomitant medications: review other drugs that may affect glucose levels or insulin action. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Basal can interact with several medicines; awareness helps maintain safety.

Major Interactions (Avoid): - Sulfonylureas or meglitinides: additive hypoglycaemia risk. - Beta‑blockers: may mask hypoglycaemia symptoms. - MAO inhibitors: unpredictable alterations in glucose control.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose. - Systemic corticosteroids: can increase insulin requirements. - ACE inhibitors or ARBs: monitor renal function and potassium levels.